Genefirst have developed a COVID-19 test

August 24th 2020

We have developed a simple to use COVID-19 molecular diagnostic test which can be used in clinical laboratories to process patient samples and to detect those positive for COVID-19.

We have since extended this development to include other common flu season pathogens, such as Influenza and RSV in our test, to support effective screening and triage of symptomatic patients. With the support of our network across Europe we will be conducting clinical studies to determine the utility and effectiveness of adopting these assays into the healthcare system, such as the NHS. Whilst COVID development is a top priority, GeneFirst continues to develop and launch oncology tests for use with liquid biopsies, and to grow the team as part of the business plan for expansion. - Winnie Wu, CEO GeneFirst Limited

November 30th 2023

Customer Connection: CFS

Commonwealth Fusion Systems (CFS) is an American fusion power company founded in 2018 in Cambridge, Massachusetts after a spin-out from the Massachusetts Institute of Technology (MIT). We got the opportunity to speak with Anthony Hollingsworth, Principal Tritium Scientist at CFS, to find out more about their company and its ambitions […]

November 16th 2023

Customer Connection: Oxitec Ltd

Oxitec is the leading developer of biological solutions to control pests that transmit disease, destroy crops, and harm livestock. We got the opportunity to speak with Sanjay Basu, Molecular Biology Team Lead of Oxitec, to find out more about their experience at Culham Innovation Centre, and their company’s plans for […]

November 2nd 2023

5 minutes with: Sigma Lithium

Sigma Lithium Ltd is an innovative company that is known widely for their invention of the 3D lithium anode material used for fast charging lithium batteries. We got the chance to have a chat with director and CEO Gleb Ivanov, discussing the material they manufacture, their experience at Culham Innovation […]